Ong, S.W.X.; Ren, D.; Lee, P.H.; Sutjipto, S.; Dugan, C.; Khoo, B.Y.; Tay, J.X.; Vasoo, S.; Young, B.E.; Lye, D.C.
Real-World Use of Sotrovimab for Pre-Emptive Treatment in High-Risk Hospitalized COVID-19 Patients: An Observational Cross-Sectional Study. Antibiotics 2022, 11, 345.
https://doi.org/10.3390/antibiotics11030345
AMA Style
Ong SWX, Ren D, Lee PH, Sutjipto S, Dugan C, Khoo BY, Tay JX, Vasoo S, Young BE, Lye DC.
Real-World Use of Sotrovimab for Pre-Emptive Treatment in High-Risk Hospitalized COVID-19 Patients: An Observational Cross-Sectional Study. Antibiotics. 2022; 11(3):345.
https://doi.org/10.3390/antibiotics11030345
Chicago/Turabian Style
Ong, Sean W. X., Dongdong Ren, Pei Hua Lee, Stephanie Sutjipto, Christopher Dugan, Bo Yan Khoo, Jun Xin Tay, Shawn Vasoo, Barnaby E. Young, and David C. Lye.
2022. "Real-World Use of Sotrovimab for Pre-Emptive Treatment in High-Risk Hospitalized COVID-19 Patients: An Observational Cross-Sectional Study" Antibiotics 11, no. 3: 345.
https://doi.org/10.3390/antibiotics11030345
APA Style
Ong, S. W. X., Ren, D., Lee, P. H., Sutjipto, S., Dugan, C., Khoo, B. Y., Tay, J. X., Vasoo, S., Young, B. E., & Lye, D. C.
(2022). Real-World Use of Sotrovimab for Pre-Emptive Treatment in High-Risk Hospitalized COVID-19 Patients: An Observational Cross-Sectional Study. Antibiotics, 11(3), 345.
https://doi.org/10.3390/antibiotics11030345
